Johnson & Johnson's (JNJ.US) EGFR/cMET bispecific antibody "evametamab subcutaneous injection" has been submitted for approval

On September 25, the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) website showed that Johnson & Johnson's (JNJ.US) evolocumab injection (subcutaneous injection) had been accepted for review. This is the first time that evolocumab subcutaneous injection has been submitted for approval in China.